Axsome Therapeutics, Inc. (AXSM) Q3 2023 Earnings Results

Axovant Misses on EPS, Stock Down 4.18%

Axovant's earnings report showed a larger-than-expected loss per share, which contributed to a 4.18% drop in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's financial health and future performance. The focus on clinical trials suggests that management is prioritizing long-term growth over short-term results.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.32	N/A	-6.19%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding the current financial outlook. They emphasized the importance of their ongoing research efforts.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The focus remains on ongoing clinical trials and product development.

Axovant Misses on EPS, Stock Down 4.18%

Key numbers

Management commentary

Axsome Therapeutics, Inc.

More earnings this week

Axovant Misses on EPS, Stock Down 4.18%

Key numbers

Management commentary